Boji Medical Technology Co

Boji Medical Technology Co Current Liabilities

The Current Liabilities of Boji Medical Technology Co (300404.SZ) as of Nov 1, 2026 is 186.50 M CNY. In the previous year, Current Liabilities was 174.24 M CNY — a change of 7.03% (higher).

Current Liabilities

186.50 MCNY

YoY

7.03%

Last updated:

Current Liabilities of Boji Medical Technology Co is 2025 186.50 M CNY. Current Liabilities of Boji Medical Technology Co was 2024 174.24 M CNY. It decreases by 7.03% higher compared to the previous year.

The Boji Medical Technology Co Current Liabilities history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Current Liabilities
Date
Current Liabilities
Jan 1, 2018
165.17 M CNY
Jan 1, 2019
160.96 M CNY
Jan 1, 2020
219.22 M CNY
Jan 1, 2021
253.11 M CNY
Jan 1, 2022
114.53 M CNY
Jan 1, 2023
143.40 M CNY
Jan 1, 2024
174.24 M CNY
Jan 1, 2025
186.50 M CNY
The Boji Medical Technology Co Current Liabilities history
YEARCurrent LiabilitiesYoY
186.50 MCNY+7.03%
174.24 MCNY+21.51%
143.40 MCNY+25.21%
114.53 MCNY-54.75%
253.11 MCNY+15.46%
219.22 MCNY+36.19%
160.96 MCNY-2.55%
165.17 MCNY+8.65%
152.02 MCNY+82.77%
83.18 MCNY+2.37%
81.25 MCNY-10.04%
90.32 MCNY+6.66%
84.68 MCNY+36.96%
61.83 MCNY—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Boji Medical Technology Co Stock analysis

What does Boji Medical Technology Co do? Boji Medical Technology Co., Ltd. generates revenue through comprehensive CRO services for pharmaceutical and medical device development. The company offers preclinical research, clinical trials, data management, biostatistics, and regulatory consulting, primarily serving domestic pharmaceutical companies and research institutions. Their one-stop service model includes drug evaluation, medical device registration, and CDMO services for new drug and device production. The firm's domestic market focus ensures steady demand from local clients seeking regulatory compliance and R&D support. The company's revenue streams are derived from multiple service segments: preclinical studies, clinical research, and technology transfer. These services are tailored to meet the needs of pharmaceutical firms requiring outsourced R&D solutions. CDMO services further enhance their offerings by supporting manufacturing processes alongside development. Domestic clients form the core customer base, leveraging Boji's expertise in navigating China's regulatory landscape for drug and device approvals. Boji Medical Technology's business model centers on providing end-to-end CRO solutions, combining preclinical and clinical research with regulatory support. Their services are designed to accelerate product development cycles for clients, reducing time-to-market for new pharmaceuticals and medical devices. The firm's domestic market strategy aligns with the growing demand for R&D outsourcing within China's healthcare sector. Boji Medical Technology Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Boji Medical Technology Co stock

Current Liabilities of Boji Medical Technology Co is 186.50 M CNY in 2025.

Current Liabilities of Boji Medical Technology Co changed from 174.24 M CNY to 186.50 M CNY, representing a 7.03% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Current Liabilities Boji Medical Technology Co since 2006 – with annual values, charts, and detailed analysis.

Current liabilities are obligations due within one year, including accounts payable, short-term debt, and accrued expenses.

Current Liabilities's CNY is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Current Liabilities's Boji Medical Technology Co historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — Boji Medical Technology Co

All Key Metrics — Boji Medical Technology Co